Immunohistochemical detection of XIAP and p63 in adenomatous hyperplasia, atypical adenomatous hyperplasia, bronchioloalveolar carcinoma and well-differentiated adenocarcinoma

Modern Pathology

Volumn 21, Issue 5, 2008, Pages 553-558

  Wu, Maoxin ^a   Orta, Lurmag ^a   Gil, Joan ^a   Li, Gan ^a   Hu, Alice ^a   Burstein, David E ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Adenomatous hyperplasia; Atypical adenomatous hyperplasia; Bronchioloalveolar carcinoma and well differentiated adenocarcinoma; p63; XIAP

Indexed keywords

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY P63; MONOCLONAL ANTIBODY XIAP; PROTEIN P63; X LINKED INHIBITOR OF APOPTOSIS;

ARTICLE; CHROMOSOME ABERRATION; CLINICAL ARTICLE; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; HISTOGENESIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG ADENOMA; LUNG ALVEOLUS CELL; LUNG ALVEOLUS CELL CARCINOMA; PRECANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL;

ADENOCARCINOMA; ADENOCARCINOMA, BRONCHIOLO-ALVEOLAR; DIAGNOSIS, DIFFERENTIAL; HUMANS; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; LUNG; LUNG NEOPLASMS; MEMBRANE PROTEINS; PRECANCEROUS CONDITIONS; TUMOR MARKERS, BIOLOGICAL; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 42549103131     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2008.5     Document Type: Article

References (34)

1. Brambilla E, Travis WD, Colby TV, et al. The new world health organization classification of lung tumours. Eur Respir J 2001;18:1059-1068.
2. Crook NE, Clem RJ, Miller LK. An apoptosis-inhibiting baculovirus gene with a zinc finger-like motif. J Virol 1993;67:2168-2174.
3. Yang YL, Li XM. The IAP family: endogenous caspase inhibitors with multiple biological activities. Cell Res 2000;10:169-177.
4. Holcik M, Gibson H, Korneluk RG. XIAP: apoptotic brake and promising therapeutic target. Apoptosis 2001;6:253-261.
5. Schimmer AD, Dalili S, Batey RA, et al. Targeting XIAP for the treatment of malignancy. Cell Death Differ 2006;13:179-188.
6. Berezovskaya O, Schimmer AD, Glinskii AB, et al. Increased expression of apoptosis inhibitor protein XIAP contributes to anoikis resistance of circulating human prostate cancer metastasis precursor cells. Cancer Res 2005;65:2378-2386.
7. Holcik M, Yeh C, Korneluk RG, et al. Translational upregulation of X-linked inhibitor of apoptosis (XIAP) increases resistance to radiation induced cell death. Oncogene 2000;19:4174-4177.
8. Tong QS, Zheng LD, Wang L, et al. Downregulation of XIAP expression induces apoptosis and enhances chemotherapeutic sensitivity in human gastric cancer cells. Cancer Gene Ther 2005;12:509-514.
9. Chawla-Sarkar M, Bae SI, Reu FJ, et al. Down regulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis. Cell Death Differ 2004;11:915-923.
10. Sasaki H, Sheng Y, Kotsuji F, et al. Down-regulation of X-linked inhibitor of apoptosis protein induces apoptosis in chemoresistant human ovarian cancer cells. Cancer Res 2000;60:5659-5666.
11. McManus DC, Lefebvre CA, Cherton-Horvat G, et al. Loss of XIAP protein expression by RNAi and antisense approaches sensitizes cancer cells to functionally diverse chemotherapeutics. Oncogene 2004;23:8105-8117.
12. Kim JS, Eom JI, Cheong JW, et al. Protein kinase CK2alpha as an unfavorable prognostic marker and novel therapeutic target in acute myeloid leukemia. Clin Cancer Res 2007;13:1019-1028.
13. Muris JJ, Cillessen SA, Vos W, et al. Immunohistochemical profiling of caspase signaling pathways predicts clinical response to chemotherapy in primary nodal diffuse large B-cell lymphomas. Blood 2005;105:2916-2923.
14. Mizutani Y, Nakanishi H, Li YN, et al. Overexpression of XIAP expression in renal cell carcinoma predicts a worse prognosis. Int J Oncol 2007;4:919-925.
15. Vischioni B, van der Valk P, Span SW, et al. Expression and localization of inhibitor of apoptosis proteins in normal human tissues. Hum Pathol 2006;37:78-86.
16. Kamsteeg M, Rutherford T, Sapi E, et al. Phenoxodiol - an isoflavone analog - induces apoptosis in chemoresistant ovarian cancer cells. Oncogene 2003;22:2611-2620.
17. Rutherford TD, Makkenchery A, Mor G. Phenoxodiol phase Ib/II study in patients with recurrent ovarian cancer that are resistant to second line chemotherapy. J Soc Gynecol Invest 2004;11:254.
18. Checinska A, Hoogeland BS, Rodriguez JA, et al. Role of XIAP in inhibiting cisplatin-induced caspase activation in non-small cell lung cancer cells: a small molecule Smac mimic sensitizes for chemotherapy-induced apoptosis by enhancing caspase-3 activation. Exp Cell Res 2006;313:1215-1224.
19. Dong F, Guo W, Zhang L, et al. Downregulation of XIAP and induction of apoptosis by the synthetic cyclin-dependent kinase inhibitor GW8510 in non-small cell lung cancer cells. Cancer Biol Ther 2006;5:165-170.
20. Cao C, Mu Y, Hallahan DE, et al. XIAP and survivin as therapeutic targets for radiation sensitization in preclinical models of lung cancer. Oncogene 2004;23:7047-7052.
21. Hu Y, Cherton-Horvat G, Dragowska V, et al. Antisense oligonucleotides targeting XIAP induce apoptosis and enhance chemotherapeutic activity against human lung cancer cells in vitro and in vivo. Clin Cancer Res 2003;9:2826-2836.
22. Wu M, Yuan S, Szporn AH, et al. Immunocytochemical detection of XIAP in body effusion and washes. Mod Pathol 2005;18:1618-1622.
23. Sheikh HA, Fuhrer K, Cieply K, et al. P63 expression in assessment of bronchioloalveolar proliferations of the lung. Mod Pathol 2004;17:1134-1140.
24. Wu M, Wang B, Gil J, et al. p63 and TTF-1 Immunostaining: a useful marker panel for distinguishing small cell carcinoma of lung from poorly differentiated squamous cell carcinoma of lung. Am J Clin Pathol 2003;119:696-702.
25. Shtilbans V, Szporn AH, Wu M, et al. p63 immunostaining in destained bronchoscopic cytologic specimen. Diagn Cytopathol 2005;32:198-203.
26. Wu M, Zhang D, Szporn AH, et al. Cytology applications of p63 and TTF-1 immunostaining in differential diagnosis of poorly differentiated primary and secondary lung cancers. Diagn Cytopathol 2005;33:1-5.
27. Wang BY, Gil J, Kaufman D, et al. P63 in pulmonary epithelium, pulmonary squamous neoplasms, and other pulmonary tumors. Hum Pathol 2002;33:921-926.
28. Pelosi G, Pasini F, Stenholm CO. p63 immunoreactivity in lung cancer: yet another player in the development of squamous cell carcinomas? J Pathol 2002;198:100-108.
29. Ghaffar H, Sahin F, Sanchez-Cepedes M, et al. LKB1 protein expression in the evolution of glandular neoplasia of the lung. Clin Cancer Res 2003;9:2998-3003.
30. Tominaga M, Sueoka N, Irie K, et al. Detection and discrimination of preneoplastic and early stages of lung adenocarcinoma using hnRNP B1 combined with the cell cycle-related markers p16, cyclin D1, and Ki-67. Lung Cancer 2003;40:45-53.
31. Jaffer S, Orta L, Sunkara S, et al. Immunohistochemical detection of anti-apoptotic protein XIAP in mammary carcinoma. Hum Pathol 2007;38:864-870.
32. Nagi C, Xiao G-Q, Li G, et al. Immunohistochemical detection of XIAP in head and neck squamous cell carcinoma. Annal Diagn Pathol 2007;11:402-406.
33. Burstein DE, Idrees MT, Li G, et al. Immunohistochemical detection of XIAP in cervical squamous intraepithelial neoplasia and squamous carcinoma. Annal Diagn Pathol (in press).
34. Narahashi T, Niki T, Wang T, et al. Cytoplasmic localization of p63 is associated with poor patient survival in lung adenocarcinoma. Histopathology 2006;49:349-357.